Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

75 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
LINE1 are spliced in non-canonical transcript variants to regulate T cell quiescence and exhaustion.
Marasca F, Sinha S, Vadalà R, Polimeni B, Ranzani V, Paraboschi EM, Burattin FV, Ghilotti M, Crosti M, Negri ML, Campagnoli S, Notarbartolo S, Sartore-Bianchi A, Siena S, Prati D, Montini G, Viale G, Torre O, Harari S, Grifantini R, Soldà G, Biffo S, Abrignani S, Bodega B. Marasca F, et al. Among authors: grifantini r. Nat Genet. 2022 Feb;54(2):180-193. doi: 10.1038/s41588-021-00989-7. Epub 2022 Jan 17. Nat Genet. 2022. PMID: 35039641
ERMP1, a novel potential oncogene involved in UPR and oxidative stress defense, is highly expressed in human cancer.
Grandi A, Santi A, Campagnoli S, Parri M, De Camilli E, Song C, Jin B, Lacombe A, Castori-Eppenberger S, Sarmientos P, Grandi G, Viale G, Terracciano L, Chiarugi P, Pileri P, Grifantini R. Grandi A, et al. Among authors: grifantini r. Oncotarget. 2016 Sep 27;7(39):63596-63610. doi: 10.18632/oncotarget.11550. Oncotarget. 2016. PMID: 27566589 Free PMC article.
TCTN2: a novel tumor marker with oncogenic properties.
Cano-Rodriguez D, Campagnoli S, Grandi A, Parri M, Camilli E, Song C, Jin B, Lacombe A, Pierleoni A, Bombaci M, Cordiglieri C, Ruiters MH, Viale G, Terracciano L, Sarmientos P, Abrignani S, Grandi G, Pileri P, Rots MG, Grifantini R. Cano-Rodriguez D, et al. Among authors: grifantini r. Oncotarget. 2017 Aug 24;8(56):95256-95269. doi: 10.18632/oncotarget.20438. eCollection 2017 Nov 10. Oncotarget. 2017. PMID: 29221125 Free PMC article.
Novel biomarkers for primary biliary cholangitis to improve diagnosis and understand underlying regulatory mechanisms.
Bombaci M, Pesce E, Torri A, Carpi D, Crosti M, Lanzafame M, Cordiglieri C, Sinisi A, Moro M, Bernuzzi F, Gerussi A, Geginat J, Muratori L, Terracciano LM, Invernizzi P, Abrignani S, Grifantini R. Bombaci M, et al. Among authors: grifantini r. Liver Int. 2019 Nov;39(11):2124-2135. doi: 10.1111/liv.14128. Epub 2019 May 15. Liver Int. 2019. PMID: 31033124
Integrated longitudinal immunophenotypic, transcriptional and repertoire analyses delineate immune responses in COVID-19 patients.
Notarbartolo S, Ranzani V, Bandera A, Gruarin P, Bevilacqua V, Putignano AR, Gobbini A, Galeota E, Manara C, Bombaci M, Pesce E, Zagato E, Favalli A, Sarnicola ML, Curti S, Crosti M, Martinovic M, Fabbris T, Marini F, Donnici L, Lorenzo M, Mancino M, Ungaro R, Lombardi A, Mangioni D, Muscatello A, Aliberti S, Blasi F, De Feo T, Prati D, Manganaro L, Granucci F, Lanzavecchia A, De Francesco R, Gori A, Grifantini R, Abrignani S. Notarbartolo S, et al. Among authors: grifantini r. Sci Immunol. 2021 Aug 10;6(62):eabg5021. doi: 10.1126/sciimmunol.abg5021. Sci Immunol. 2021. PMID: 34376481 Free article.
Impaired seroconversion after SARS-CoV-2 mRNA vaccines in patients with solid tumours receiving anticancer treatment.
Amatu A, Pani A, Patelli G, Gagliardi OM, Loparco M, Piscazzi D, Cassingena A, Tosi F, Ghezzi S, Campisi D, Grifantini R, Abrignani S, Siena S, Scaglione F, Sartore-Bianchi A. Amatu A, et al. Among authors: grifantini r. Eur J Cancer. 2022 Mar;163:16-25. doi: 10.1016/j.ejca.2021.12.006. Epub 2021 Dec 22. Eur J Cancer. 2022. PMID: 35032813 Free PMC article.
Exosomes Recovered From the Plasma of COVID-19 Patients Expose SARS-CoV-2 Spike-Derived Fragments and Contribute to the Adaptive Immune Response.
Pesce E, Manfrini N, Cordiglieri C, Santi S, Bandera A, Gobbini A, Gruarin P, Favalli A, Bombaci M, Cuomo A, Collino F, Cricrì G, Ungaro R, Lombardi A, Mangioni D, Muscatello A, Aliberti S, Blasi F, Gori A, Abrignani S, De Francesco R, Biffo S, Grifantini R. Pesce E, et al. Among authors: grifantini r. Front Immunol. 2022 Jan 17;12:785941. doi: 10.3389/fimmu.2021.785941. eCollection 2021. Front Immunol. 2022. PMID: 35111156 Free PMC article.
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations.
Favalli A, Favalli EG, Gobbini A, Zagato E, Bombaci M, Maioli G, Pesce E, Donnici L, Gruarin P, Biggioggero M, Curti S, Manganaro L, Marchisio E, Bevilacqua V, Martinovic M, Fabbris T, Sarnicola ML, Crosti M, Marongiu L, Granucci F, Notarbartolo S, Bandera A, Gori A, De Francesco R, Abrignani S, Caporali R, Grifantini R. Favalli A, et al. Among authors: grifantini r. Front Immunol. 2022 Jun 10;13:873195. doi: 10.3389/fimmu.2022.873195. eCollection 2022. Front Immunol. 2022. PMID: 35757699 Free PMC article.
75 results